Hutchison China MediTech Limited (HCM): Price and Financial Metrics


Hutchison China MediTech Limited (HCM): $13.88

0.60 (+4.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HCM to Watchlist
Sign Up

Industry: China


Ranked

of

in industry

HCM POWR Grades


  • Stability is the dimension where HCM ranks best; there it ranks ahead of 68.03% of US stocks.
  • HCM's strongest trending metric is Quality; it's been moving down over the last 179 days.
  • HCM ranks lowest in Quality; there it ranks in the 6th percentile.

HCM Stock Summary

  • Of note is the ratio of HUTCHMED (China) Ltd's sales and general administrative expense to its total operating expenses; merely 13.68% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for HUTCHMED (China) Ltd is higher than it is for about merely 12.95% of US stocks.
  • As for revenue growth, note that HCM's revenue has grown 70.02% over the past 12 months; that beats the revenue growth of 87.62% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to HUTCHMED (China) Ltd are HIMX, VNE, GLPG, VCNX, and NVEC.
  • HCM's SEC filings can be seen here. And to visit HUTCHMED (China) Ltd's official web site, go to www.hutch-med.com.

HCM Valuation Summary

  • In comparison to the median Healthcare stock, HCM's price/sales ratio is 455.26% higher, now standing at 21.1.
  • Over the past 66 months, HCM's EV/EBIT ratio has gone down 177.6.
  • Over the past 66 months, HCM's EV/EBIT ratio has gone down 177.6.

Below are key valuation metrics over time for HCM.

Stock Date P/S P/B P/E EV/EBIT
HCM 2021-08-31 21.1 6.0 -33.0 -30.8
HCM 2021-08-30 20.0 5.6 -31.2 -28.9
HCM 2021-08-27 19.6 5.5 -30.6 -28.4
HCM 2021-08-26 19.4 5.5 -30.3 -28.0
HCM 2021-08-25 19.8 5.6 -31.0 -28.8
HCM 2021-08-24 20.4 5.8 -31.8 -29.6

HCM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HCM has a Quality Grade of D, ranking ahead of 20.42% of graded US stocks.
  • HCM's asset turnover comes in at 0.31 -- ranking 145th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows HCM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.310 0.181 -0.401
2020-12-31 0.383 0.173 -0.384
2020-06-30 0.410 0.212 -0.305
2019-12-31 0.419 0.218 -0.337
2019-06-30 0.399 0.296 -0.220
2018-12-31 0.379 0.328 -0.171

HCM Stock Price Chart Interactive Chart >

Price chart for HCM

HCM Price/Volume Stats

Current price $13.88 52-week high $43.18
Prev. close $13.28 52-week low $8.40
Day low $13.47 Volume 225,800
Day high $14.01 Avg. volume 526,960
50-day MA $12.01 Dividend yield N/A
200-day MA $21.76 Market Cap 2.40B

Hutchison China MediTech Limited (HCM) Company Bio


Hutchison China MediTech Limited engages in the research, development, manufacture, and sale of pharmaceuticals and health-related consumer products primarily in China. The company was founded in 2000 and is based in Hong Kong, Hong Kong.


HCM Latest News Stream


Event/Time News Detail
Loading, please wait...

HCM Latest Social Stream


Loading social stream, please wait...

View Full HCM Social Stream

Latest HCM News From Around the Web

Below are the latest news stories about HUTCHMED (China) Ltd that investors may wish to consider to help them evaluate HCM as an investment opportunity.

Genetron Health Announces Companion Diagnostic Collaboration Agreement with HUTCHMED’s ORPATHYS® for NSCLC

BEIJING, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has signed a collaboration agreement with HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) for the joint development of a companion diagnostic (CDx) test for

Yahoo | February 10, 2022

HUTCHMED to Announce 2021 Final Results

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2021 on Thursday, March 3, 2022 at 7:00 am Eastern Standard Time (EST) / 12:00 noon Greenwich Mean Time (GMT) / 8:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management.

Yahoo | February 7, 2022

HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 04, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase Ib/II study in China of HMPL-453, an investigational novel selective inhibitor targeting fibroblast growth factor receptors (“FGFR”) 1/2/3, in combination with chemotherapy or the anti-PD-1 therapy, toripalimab. The first patient received their first dose on January 22, 2022. The clinical trial is a m

Yahoo | February 4, 2022

HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I trial in China of HMPL-653, an investigational novel, highly selective, and potent colony-stimulating factor 1 receptor (“CSF-1R”) inhibitor. The first patient received their first dose on January 18, 2022. The Phase I trial is a multicenter, open-label, single-arm study to evaluate the safety, tolerability,

Yahoo | January 20, 2022

HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that updated analysis of the ongoing international Phase I/Ib trial of fruquintinib will be presented at the upcoming 2022 ASCO Gastrointestinal Cancers Symposium, taking place on January 20-22, 2022. The meeting will be held virtually and in person at the Moscone Center in San Francisco, California, US. Further details of the presenta

Yahoo | January 19, 2022

Read More 'HCM' Stories Here

HCM Price Returns

1-mo -10.57%
3-mo 39.50%
6-mo -48.78%
1-year -66.90%
3-year -33.59%
5-year -49.53%
YTD -60.43%
2021 9.56%
2020 27.72%
2019 8.58%
2018 -41.43%
2017 190.49%

Continue Researching HCM

Want to see what other sources are saying about Hutchison China MediTech Ltd's financials and stock price? Try the links below:

Hutchison China MediTech Ltd (HCM) Stock Price | Nasdaq
Hutchison China MediTech Ltd (HCM) Stock Quote, History and News - Yahoo Finance
Hutchison China MediTech Ltd (HCM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5376 seconds.